News & Trade Shows

News & Trade shows


Biomerica Announces Executive Advisor Appointment
1/8/2016
 

Biomerica Announces Executive Advisor Appointment for Medical Affairs and Research

Irvine, Calif. – January 08, 2016 --
Biomerica Inc. (OTCBB: BMRA) announced today the appointment of Charles A. Carter, PharmD, MBA, as a senior advisor with the main responsibilities of Executive Director of Medical Affairs and Research. He will work with the company’s Scientific Advisory Board and management to develop and implement strategies to successfully guide products through developmental and regulatory FDA processes.

Dr. Carter is the former Executive Director of Medical Affairs for Salix Pharmaceuticals. He managed the Medical Affairs activities of this growing and dynamic organization. He was active in the success of Salix in receiving FDA clearance for its IBS-D drug, Xifaxan® (rifaximin), in 2015.  Dr. Carter is well experienced in clinical development and clinical operations. Prior to that Dr. Carter, founded Pharmaceutical Strategic Initiatives, LLC. PSI became a leading provider of strategic consulting, clinical research design and strategy, regulatory preparation, medical and scientific content creation, and health outcomes research for the pharmaceutical industry.

"We are excited to have Chuck on our team and look forward to the contributions he will bring in driving the clinical development and studies for our IBS pipeline," said Zackary Irani, Biomerica CEO. "His broad experience and strong leadership will further strengthen Biomerica’s clinical program in IBS.”
 
“I am excited to assist the Biomerica team, one that is committed to identifying and providing products to help patients and sufferers of IBS and other medical conditions” stated Dr. Carter.

About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and  in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases.   The Company’s products are designed to enhance the health and well being of people, while reducing total healthcare costs.  Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, prospects, new products, favorable outlook, new distributors, expansion, increases in productivity and margins, expected orders, leading market positions, anticipated future sales or production volume of the Company, the launch or success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.